Experimental replacement therapy counters decreased IGF-1 levels in Huntington’s disease
Ontology highlight
ABSTRACT: Huntington’s disease (HD) is a monogenetic neurodegenerative disorder caused by the expansion of a polyglutamine (polyQ) stretch in huntingtin (htt). Here we show that mutant htt reduces the transcription of insulin-like growth factor 1 (IGF-1) and leads to loss of IGF-1 in HD brains, HD mouse models and mutant htt-transgenic microglial cells. IGF-1 replacement therapy by transplantation of genetically engineered mouse neuronal precursor cells (mNPCs) in a mouse model of HD reverted the motor phenotype and countered striatal neuronal loss.
ORGANISM(S): Mus musculus
PROVIDER: GSE19291 | GEO | 2018/10/01
REPOSITORIES: GEO
ACCESS DATA